1,267 results on '"M. Mohty"'
Search Results
2. S236: RANDOMIZED MULTICENTER PHASE III STUDY OF HAPLO VERSUS HLA-MATCHED UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS
- Author
-
S. Harbi, J.-M. Boher, E. Forcade, P. Chevallier, R. Peffault De Latour, F. Malard, S. Francois, A. Charbonnier, E. Hermet, C. E. Bulabois, A. Huynh, A. Berceanu, T. Cluzeau, M. T. Rubio, S. Furst, R. devillier, M. Mohty, and D. Blaise more...
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
Catalog
3. S238: MATCHED RELATED VERSUS UNRELATED VERSUS HAPLOIDENTICAL DONORS FOR ALLOGENEIC TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT
- Author
-
A. Nagler, M. Labopin, S. Mielke, J. Passweg, D. Blaise, T. Gedde-Dahl, J. J. Cornelissen, U. Salmenniemi, I. Yakoub-Agha, P. Reményi, G. Socié, G. Van Gorkom, H. Labussière-Wallet, X.-J. Huang, M. Thérèse Rubio, J. L Byrne, C. Craddock, L. Griskevicius, F. Ciceri, and M. Mohty more...
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
4. P529: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH FIRST-IN-CLASS CD123-TARGETED THERAPY TAGRAXOFUSP
- Author
-
U. Platzbecker, E. Angelucci, P. Montesinos, R. M. Lemoli, A. Spyridonidis, J. Casariego, T. I. Mughal, and M. Mohty
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
5. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE
- Author
-
A. Schavgoulidze, A. Perrot, T. Cazaubiel, X. Leleu, S. Manier, L. Buisson, S. Maheo, L. Do Souto Ferreira, R. Lannes, L. Pavageau, C. Hulin, J.-P. Marolleau, L. Voillat, K. Belhadj, M. Divoux, B. Slama, S. Brechignac, M. Macro, A.-M. Stoppa, L. Sanhes, F. Orsini-Piocelle, J. Fontan, M.-L. Chretien, H. Demarquette, M. Mohty, H. Avet-Loiseau, and J. Corre more...
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
6. P956: EMMY COHORT: MANAGEMENT OF NEWLY DIAGNOSED OR RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN PATIENTS AGED OF 80 YEARS AND OVER
- Author
-
M. Macro, O. Decaux, A. Perrot, B. Royer, M. Chretien, K. Belhadj, M. Mohty, L. Frenzel, X. Leleu, M. Dib, O. Allangba, P. Zunic, I. Botoc, J. Malfuson, P. Moreau, R. Garlantazec, N. Texier, R. Germain, C. Deal, and C. Hulin more...
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
7. P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3
- Author
-
A. M. Lesokhin, B. Arnulf, R. Niesvizky, M. Mohty, N. J. Bahlis, M. H. Tomasson, P. Rodrίguez-Otero, H. Quach, N. S. Raje, S. Iida, M.-S. Raab, A. Czibere, S. Sullivan, E. Leip, A. Viqueira, and X. Leleu more...
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
8. P1355: VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES OF DEFIBROTIDE-TREATED ADULT PATIENTS FROM THE DEFIFRANCE STUDY
- Author
-
M. Mohty, I. Yakoub-Agha, J.-H. Dalle, M. Labopin, J. Cornillon, A. Huynh, T. Lamy, C. Soussain, K. Asubonteng, D. Gutierrez, and R. Peffault de Latour
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
9. P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
- Author
-
J. Sanz-Caballer, J. Storek, G. Socié, D. Thirumalai, N. Guzman-Beccera, P. Xun, D. Kumar, N. Sadetsky, D. Dierickx, J. Reitan, A. Barlev, and M. Mohty
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
10. P1371: GRAFT-VERSUS-HOST DISEASE OFFERS NO GRAFT-VERSUS-LEUKEMIA ADVANTAGE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLO-IDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
- Author
-
A. Shimoni, C. Peczynski, M. Labopin, E. Angelucci, Y. Koc, M. Arat, J. Tischer, S. Sica, Z. Gülbas, G. Socié, D. Blaise, P. Pioltelli, H. Ozdogu, J. Vydra, F. Ciceri, A. Nagler, and M. Mohty
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
11. P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION
- Author
-
G. Basak, C. Peczynski, C. Koenecke, S. Terwel, Y. Cabrerizo, O. Penack, I. Moiseev, H. Schoemans, N. Fegueux, V. Potter, S. Zeerleder, I. Yakoub-Agha, M. Collin, U. Schanz, P. Dreger, D. Blaise, C. Besley, B. Glass, M. Mohty, C. Chabannon, J. Kuball, J. Snowden, A. Sureda, N. Kröger, and Z. Peric more...
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
12. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia
- Author
-
Simona Piemontese, F. Ciceri, M. Labopin, W. Arcese, S. Kyrcz-Krzemien, S. Santarone, H. Huang, D. Beelen, N. C. Gorin, C. Craddock, Z. Gulbas, A. Bacigalupo, M. Mohty, A. Nagler, and on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) more...
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background In the absence of a HLA-matched related or matched unrelated donor, allogeneic stem cell transplantation (allo-SCT) from mismatched unrelated donors or haploidentical donors are potential alternatives for patients with acute leukemia with an indication to allo-SCT. The objective of this study was to compare the outcome of allo-SCT from T cell-replete haploidentical (Haplo) versus matched (MUD 10/10) or mismatched unrelated donor at a single HLA-locus (MMUD 9/10) for patients with acute leukemia in remission. Methods Two hundred sixty-five adult patients with de novo acute leukemia in first or second remission that received a Haplo-SCT between January 2007 and December 2013 were compared with 2490 patients receiving a MUD 10/10 and 813 receiving a MMUD 9/10. Propensity score weighted analysis was conducted in order to control for disease risk imbalances between the groups. Results The weighted 3-year non-relapse mortality and relapse incidence were 29 and 30% for Haplo, 21 and 29% for MUD 10/10, and 29 and 25% for MMUD 9/10, respectively. The weighted 3-year leukemia-free survival (LFS) and overall survival (OS) were 41 and 46% for Haplo, 50 and 56% for MUD 10/10, and 46 and 48% for MMUD 9/10, respectively. Using weighted Cox model, both LFS and OS were significantly higher in transplants from MUD 10/10 compared from those in Haplo but not different between transplants from MMUD 9/10 and Haplo. The type of donor was not significantly associated with neither acute nor chronic graft-versus-host disease. Conclusions Patients with acute leukemia in remission have better outcomes if transplanted from a MUD 10/10. We did not find any significant difference in outcome between transplants from MMUD 9/10 and Haplo, suggesting that both can be equally used in the absence of a 10/10 MUD. Key point 1 Better outcomes using fully (10/10) matched unrelated donor for allo-SCT in acute leukemia in remission. Key point 2 Similar outcomes after allo-SCT from unmanipulated haploidentical graft or mismatched (9/10) unrelated donor in acute leukemia in remission. more...
- Published
- 2017
- Full Text
- View/download PDF
13. DEFIBROTIDE TREATMENT IN PAEDIATRIC PATIENTS WITH SEVERE/VERY SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION: DEFIFRANCE INTERIM RESULTS
- Author
-
V. Gandemer, P. Schneider, A. Sirvent, R. Martin, V. Bouvatier, M. Labopin, and M. Mohty
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2020
- Full Text
- View/download PDF
14. ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY
- Author
-
M Mohty, M Tomasson, B Arnulf, N Bahlis, M Prince, R Niesvizky, P Rodrgue-Otero, J Martine-Lopez, G Koehne, Y Jethava, A Gabayan, D Stevens, A Nooka, N Raje, S Iida, E Leip, U Conte, A Czibere, A Viqueira, V Blunk, and A Lesokhin more...
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Introduction/Objectives: To report the findings of extended follow-up and biweekly administration of elranatamab monotherapy in patients (pts) with relapsed/refractory multiple myeloma (RRMM) naïve to BCMA-directed therapies enrolled in Cohort A of MagnetisMM-3. Materials and methods: MagnetisMM-3 (NCT04649359) is an open-label, multicenter, registration phase 2 study evaluating the efficacy and safety of elranatamab monotherapy in pts with RRMM. Eligible pts were refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 antibody. Pts received subcutaneous elranatamab in 28-d cycles with step-up doses of 12 mg on cycle 1 day 1 (C1D1) and 32 mg on C1D4 followed by 76 mg once-weekly beginning C1D8. Pts treated for 6 cycles and achieving partial response (PR) or better, lasting ≥2 mo, were switched to 76 mg once every two weeks (Q2W). Results: Overall, 123 pts received elranatamab. Median pt age was 68.0 y (range, 36-89); 63.4% of pts had an ECOG PS ≥1. The median number of prior lines of therapy was 5.0 (2-22), with 96.7% and 42.3% of pts having triple-class- and penta-drug refractory disease, respectively. At data cutoff (≍12 mo after last pt initial dose), the median follow up was 12.8 mo (0.2-22.7); 34.1% of pts remained on treatment. The most common reasons for treatment discontinuation were progressive disease (39.0%) and adverse events (AE; 13.8%). Objective response rate per blinded independent central review (BICR) was 61% (95% CI 51.8-69.6), with 39 (31.7%) pts with complete response (CR) or stringent CR (sCR); very good partial response (VGPR) and PR were achieved in 29 (23.6%) and 7 (5.7%) pts, respectively. MRD-negativity (threshold 10−−5) was achieved by 92.0% (n = 23/25) of evaluable pts. Median duration of response (mDOR) has not been reached (95% CI 12.9-NE), and DOR at 12 mo was 74.1% (95% CI 60.5-83.6). In pts with CR/sCR or VGPR, mDOR was not reached by 12 mo; in pts with PR, mDOR was 5.2 mo (95% CI 1.6-NE). There were 46 responders by BICR who switched to Q2W dosing ≥24 wk prior to the data cutoff; among these pts, 80.4% maintained/improved their response ≥24 wk after the switch. Median progression-free and overall survival have not been reached by 12 mo, and the respective rates (95% CI) at 12 mo were 57.1% (47.2-65.9) and 62.0% (52.8-70.0). Most common grade 3/4 treatment emergent AEs were hematologic; grade 3/4 nonhematologic events reported in ≥5% of pts were COVID-pneumonia (10.6%), hypokalemia (9.8%), pneumonia (7.3%), sepsis (6.5%), hypertension (6.5%), ALT increased (5.7 %), and SARS-COV-2 test positive (5.7%). Among pts who switched to Q2W dosing (n = 58), the incidence of grade 3/4 AEs decreased by >10% after the switch. Discussion: Elranatamab remains efficacious and well tolerated in pts with RRMM after >1 y of follow-up. Updated analysis with a median follow-up of ≍15 mo, the longest of all phase 2 BCMA-CD3 bispecific antibody studies, including the outcome of pts who switched to the Q2W dosing, will be presented. Conclusion: These results support continued elranatamab development for pts with MM. more...
- Published
- 2023
- Full Text
- View/download PDF
15. EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
- Author
-
A Nooka, A Lesokhin, M Mohty, R Niesvizky, C Maisel, B Arnulf, S Larson, A Varshavsky-Yanovsky, X Leleu, L Karlin, D Vesole, N Bahlis, CF Larrea, N Raje, E Leip, U Conte, M Elmeliegy, A Viqueira, V Blunk, and S Manier more...
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Introduction/Objectives: To evaluate the efficacy and safety of elranatamab in a pooled analysis of patients (pts) enrolled in MagnetisMM trials with relapsed or refractory multiple myeloma (RRMM) who had prior exposure to B-cell maturation antigen (BCMA)-directed therapy. Materials and methods: Eligible pts received at least 1 proteasome inhibitor, 1 immunomodulatory drug, 1 anti-CD38 antibody, and 1 BCMA-directed therapy (antibody-drug conjugate [ADC] and/or chimeric antigen receptor [CAR]-T cells). The pooled analysis included pts in the MagnetisMM-1 trial (NCT03269136; n = 13) who received subcutaneous (SC) elranatamab 215-1000 μg/kg; MM-3 (NCT04649359; n = 64) and MM-9 (NCT05014412; n = 9) who received the recommended phase 2 dose of 76 mg SC once-weekly. Efficacy endpoints were evaluated by investigator per IMWG criteria. TEAEs were graded by CTCAE (MM-1, v4.03; MM-3 & MM-9, v5.0); CRS and ICANS were graded by ASTCT criteria. Results include data up through ≍10 months after last pt initial dose in all pooled studies. Results: In total, 86 pts were included. Median age was 66.0 y (range, 40-84); 47.7% male. At baseline, 69.8% had an ECOG PS ≥1; 24.4% had high risk cytogenetics; 54.7% had extramedullary disease. Pts received a median of 7.0 (3-19) prior lines of therapy, including BCMA-directed ADC (67.4%), CAR T-cells (41.9%); 9.3% received both. 96.5% and 54.7% of pts were triple-class and penta-drug refractory, respectively; among pts who received ADC and CAR-T cells respectively, 79.3% and 27.8% were refractory to ADC and CAR-T cells. After a median follow-up of 10.3 mo (0.3-32.3), median duration of treatment was 3.3 mo (0.03-30.4). At the cut-off date, 24.4% of pts remained on treatment; most common reason for permanent treatment discontinuation was progressive disease (44.2%). The overall response rate (ORR) was 45.3% (95% CI 34.6-56.5), with ≥CR achieved in 17.4% of pts. ORR for pts with prior BCMA-directed ADC and CAR-T cells was 41.4% (95% CI 28.6-55.1) and 52.8% (95% CI 35.5-69.6), respectively. Among responders, median time to objective response was 1.9 mo (0.3-9.3). Median duration of response (DOR) was not reached by 10 mo; the DOR rate at 9 mo was 72.4% (95% CI 54.7-84.2). DOR rate (95% CI) for pts with prior BCMA-directed ADC and CAR-T cells were 67.3% (43.1-83.0) and 78.9% (53.2-91.5) at 9 mo, respectively. Median progression-free survival was 4.8 mo (95% CI 1.9-7.7); median overall survival was not reached by 10 mo, with a rate of 60.1% (95% CI 48.9-69.6) at 9 mo. Most common (≥25% of pts) TEAEs were CRS (65.1% [G3 1.2%]), anemia (59.3% [G3/4, 46.5%]), neutropenia (44.2% [G3/4, 40.7%]), thrombocytopenia (40.7% [G3/4, 29.1%]), diarrhea (33.7% [G3/4, 0%], and lymphopenia (32.6% [G3/4, 30.2%]). 5.8% (G3, 2.3%) of pts. Discussion: In pts with RRMM and prior exposure to BCMA-directed therapies, elranatamab was efficacious and well tolerated; no new safety signals were observed vs the BCMA-naïve population. Conclusions: These results support treatment with elranatamab in pts with RRMM post BCMA-directed therapy. more...
- Published
- 2023
- Full Text
- View/download PDF
16. EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
- Author
-
N Raje, X Leleu, A Lesokhin, M Mohty, A Nooka, E Leip, U Conte, A Viqueira, V Blunk, and S Manier
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Introduction/Objectives: Multiple myeloma is a disease of elderly and frail people, who are often predominantly ineligible for intensive therapies. The objective of this analysis is to report the efficacy and safety of elranatamab monotherapy by age and frailty in B-cell maturation antigen-naïve patients (pts) with relapsed or refractory multiple myeloma (RRMM) enrolled into cohort A of the ongoing phase 2 MagnetisMM -3 (NCT04649359) study. Materials and methods: Eligibility criteria, dosing and administration were previously reported (Bahlis et al, ASH 2022). Subgroups of pts within Cohort A (n = 123) were analyzed by age: more...
- Published
- 2023
- Full Text
- View/download PDF
17. Allogreffe de cellules souches hématopoïétiques à partir d’un donneur haplo-identique*
- Author
-
M. Mohty and N.-C. Gorin
- Subjects
General Medicine - Published
- 2022
- Full Text
- View/download PDF
18. Neuroma Treatment With the Acellular Nerve Allograft Reconstruction Technique
- Author
-
Jennifer A Bell, Collean Trotter, Daniel Gittings, Mathew Schur, Kurt M Mohty, Rachel Lefebvre, and Milan Stevanovic
- Subjects
General Engineering - Published
- 2023
- Full Text
- View/download PDF
19. A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3
- Author
-
AM Lesokhin, B Arnulf, R Niesvizky, M Mohty, NJ Bahlis, MH Tomasson, P Rodrguez-Otero, H Quach, NS Raje, S Iida, M Raab, A Czibere, S Sullivan, E Leip, A Viqueira, V Blunk, and X Leleu
- Subjects
Immunology and Allergy ,Hematology - Published
- 2022
- Full Text
- View/download PDF
20. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations
- Author
-
M. Aljurf, D. Weisdorf, S.K. Hashmi, A. Nassar, E. Gluckman, M. Mohty, D. Rizzo, M. Pasquini, M. Hamadani, W. Saber, P. Hari, M. Kharfan-Dabaja, N. Majhail, U. Gerges, Amir Ali Hamidieh, F. Hussain, A. Elhaddad, H.K. Mahmoud, A. Tbakhi, T.B. Othman, R.M. Hamladji, M.A. Bekadja, P. Ahmed, A. Bazarbachi, S. Adil, S. Alkindi, S. Ladeb, D. Dennison, M. Patel, P. Lu, A.E. Quessar, S. Okamoto, Y. Atsuta, A. Alhejazi, M. Ayas, S.O. Ahmed, N. Novitzky, A. Srivastava, A. Seber, H. Elsolh, A. Ghavamzadeh, D. Confer, Y. Kodera, H. Greinix, J. Szer, M. Horowitz, and D. Niederwieser more...
- Subjects
Transplantation Conditioning ,lcsh:RC633-647.5 ,Hematopoietic Stem Cell Transplantation ,Hematology ,General Medicine ,lcsh:Diseases of the blood and blood-forming organs ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 ,surgical procedures, operative ,Oncology ,Socioeconomic Factors ,Humans ,Developing Countries ,Bone Marrow Transplantation - Abstract
The development of hematopoietic stem cell transplantation (HSCT) programs can face significant challenges in most developing countries because such endeavors must compete with other government health care priorities, including the delivery of basic services. While this is may be a limiting factor, these countries should prioritize development of the needed expertise to offer state of the art treatments including transplantation, by providing financial, technological, legal, ethical and other needed support. This would prove beneficial in providing successful programs customized to the needs of their population, and potentially provide long-term cost-savings by circumventing the need for their citizens to seek care abroad. Costs of establishing HSCT program and the costs of the HSCT procedure itself can be substantial barriers in developing countries. Additionally, socioeconomic factors intrinsic to specific countries can influence access to HSCT, patient eligibility for HSCT and timely utilization of HSCT center capabilities. This report describes recommendations from the Worldwide Network for Blood and Marrow Transplantation (WBMT) for establishing HSCT programs with a specific focus on developing countries, and identifies challenges and opportunities for providing this specialized procedure in the resource constrained setting. Keywords: Bone marrow transplantation, Developing countries, Low income countries more...
- Published
- 2020
21. The first steps towards a diverse and inclusive EBMT: a position paper
- Author
-
S. Montoto, J. A. Snowden, C. Chabannon, S. Corbacioglu, R. de la Camara, H. Dolstra, R. Greco, A. Gusi, N. Hamad, M. Kenyon, N. Kröger, M. Mohty, J. Murray, A. Mueller, B. Neven, R. Peffault de Latour, Z. Peric, I. Sánchez-Ortega, A. Sureda, B. Verhoeven, A. Villar, I. Yakoub-Agha, St Bartholomew's Hospital (London), Sheffield Children's NHS Foundation Trust, University of Sheffield [Sheffield], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University of Regensburg, Hospital Universitario de La Princesa, Radboud University Medical Center [Nijmegen], IRCCS San Raffaele Scientific Institute [Milan, Italie], European Society for Blood and Marrow Transplantation (EBMT), St. Vincent's Hospital, Sydney, King's College Hospital (KCH), Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Christie Hospital NHS Foundation Trust, Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Zagreb, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), HAL-SU, Gestionnaire, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU) more...
- Subjects
Transplantation ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,Hematopoietic Stem Cell Transplantation ,Humans ,Transplantation, Homologous ,Hematology ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Contains fulltext : 248819.pdf (Publisher’s version ) (Open Access)
- Published
- 2022
- Full Text
- View/download PDF
22. THE DEFIFRANCE REGISTRY STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE IN PATIENTS WITH VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING CHEMOTHERAPY
- Author
-
I Yakoub-Agha, D Blaise, J Dalle, S Labopin Md, Chantepie, J Pong, N Dronamraju, F Duchene, and M Mohty
- Subjects
Immunology and Allergy ,Hematology - Published
- 2022
- Full Text
- View/download PDF
23. Utilizing Google Trends to Track Online Interest in Elective Hand Surgery During the COVID-19 Pandemic
- Author
-
Luke T Nicholson, Jennifer A Bell, Daniel J Gittings, Milan Stevanovic, Nassim Lashkari, and Kurt M Mohty
- Subjects
medicine.medical_specialty ,google trends ,carpal tunnel ,coronavirus ,Carpal tunnel surgery ,hand surgery ,Pandemic ,medicine ,Carpal tunnel ,Elective surgery ,Carpal tunnel syndrome ,business.industry ,General surgery ,General Engineering ,google ,Hand surgery ,medicine.disease ,Orthopedics ,elective surgery ,medicine.anatomical_structure ,covid-19 ,trigger finger ,ganglion cyst ,Orthopedic surgery ,Public Health ,orthopaedic surgery ,Trigger finger ,business - Abstract
Introduction Elective hand surgery encompasses a large volume of orthopaedic cases annually. Carpal tunnel syndrome, ganglion cysts, and trigger digits are some of the most common pathologies treated by hand surgeons. In the midst of the COVID-19 pandemic, patient's interest in elective hand surgery for these conditions is uncertain. The objective of this study is to use Google Trends to track online interest in elective hand surgery in the United States during the COVID-19 pandemic. Methods Online search trends regarding elective orthopaedic hand surgery were obtained via Google Trends from November 2019 to November 2020. Three common hand pathologies in lay terms ("carpal tunnel," "‘ganglion cyst’ + ‘wrist cyst,’" and "trigger finger") and three hand surgery-specific keywords ("hand surgery," "carpal tunnel surgery," and "trigger finger surgery") were used as search terms. The search volume index (SVI) graphs for the United States for both sets of search terms were then generated from the Google Trends data and compared to the seven-day average of new COVID-19 cases per day as reported by the CDC. A separate SVI graph was then created for the search term "coronavirus” and was compared against both sets of search terms as above. Results Search trends for all elective hand pathologies and surgery-specific keywords remained constant from November 2019 to the beginning of March 2020 and then decreased significantly within a one-month period following the peak in COVID-19 cases the week of March 15, 2020. Search trends for these keywords increased to baseline levels over the next few months. The search trend for "coronavirus" demonstrated a small search volume index peak of 13 during January 2020 followed by the maximum peak of 100 during the week of March 15, 2020, corresponding to the decrease in search trends of elective hand surgery at that time. Conclusions Online interest in elective hand surgery remained constant prior to the COVID-19 pandemic; however, there was a marked decrease in search trends of elective hand surgery with the rise in daily reported COVID-19 cases, suggesting that patient's interest in elective hand surgery decreased with the onset of the pandemic. more...
- Published
- 2021
24. FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES
- Author
-
Magalie Joris, Roch Houot, Pierre Bories, René-O. Casasnovas, Emmanuel Bachy, P. Sesques, David Beauvais, Sylvain Choquet, F. Le Bras, L. Bounaix, Florence Broussais, Marie-Thérès. Rubio, Thomas Gastinne, S. Le Gouill, R. Di Blasi, François-X. Gros, Jean-Jacques Tudesq, Guillaume Cartron, F. Morschhauser, M. Mohty, Catherine Thieblemont, and Elodie Gat more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,Hematology ,General Medicine ,Car t cells ,business - Published
- 2021
- Full Text
- View/download PDF
25. AB0044 REDUCED PERIPHERAL BLOOD MYELOID CELLS IN PATIENTS WITH VEXAS SYNDROME
- Author
-
V. Jachiet, L. Ricard, P. Hirsch, F. Malard, L. P. Zhao, L. Adès, P. Fenaux, O. Fain, M. Mohty, B. Gaugler, and A. Mekinian
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy ,General Biochemistry, Genetics and Molecular Biology - Abstract
BackgroundSystemic inflammatory or dysimmune diseases (SIDDs) are encountered in up to a quarter of patients with myelodysplastic syndromes (MDS). Recently identified VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, associated with somatic mutations in UBA1, encompasses a range of severe inflammatory conditions along with hematologic abnormalities, including myelodysplasia. Only limited data are available on the pathophysiology of MDS-associated SIDDs, and especially about the role of different myeloid cell subsets.ObjectivesThe aim of this study was to describe the phenotype of myeloid immune cells (dendritic cells and monocytes) in MDS patients with associated SIDDs, and to compare their distribution with MDS patients without SIDDs and controls.MethodsPhenotype analysis by flow cytometry from PBMCs of 14 MDS patients with SIDDs, 23 MDS patients without SIDDs and 7 controls without MDS and SIDDs. Eight of the 14 MDS/SIDDs patients (57%) had a somatic UBA1 mutation.ResultsIn this study analyzing peripheral blood myeloid immune cells in MDS patients with and without SIDDs, we observed a quantitative reduction of different DC and monocyte subsets in MDS/SIDDs patients, especially in patients with active SIDDs and above all in patients with newly described VEXAS syndrome.ConclusionFurther functional studies are warranted to better understand the mechanisms and the consequences of the phenotypic modulations of immune myeloid cells in the pathophysiology of MDS-associated SIDDs, especially in VEXAS syndrome.Disclosure of InterestsNone declared more...
- Published
- 2022
- Full Text
- View/download PDF
26. Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends
- Author
-
Parvez Ahmed, Asma El Quessar, Nicolas Novitzky, East-Mediterranean (Embmt), Fazal Hussain, Mary M. Horowitz, Juliana Martinez Rolon, Lamia Torjemane, M. Mohty, Jeff Szer, African (AfBMT) Blood, Omar Fahmy, Marcelo C. Pasquini, Marrow Transplantation, Ardeshir Ghavamzadeh, Amr Nassar, Rose-Marie Hamladji, Yoshihisa Kodera, Alaa Elhaddad, Gregorio Jaimovich, Nosa Bazuaye, Miguel R. Abboud, Murtadha Al Khabori, Abdelghani Tbakhi, Nour Ben Abdejalil, Lahoucine Mahmal, Mohamed Amine Bekadja, Mickey Koh, Hassan El-Solh, Marrow Transplantation Groups, Alois Gratwohl, Salman Naseem Adil, Shahrukh K. Hashmi, Daniel J. Weisdorf, Hani Alhashmi, Mohammed Al Huneini, Mahmoud Sarhan, Mahmoud Aljurf, Helen Baldomero, Syed Ziauddin A. Zaidi, Mani Ramzi, Kristjan Paulson, Nicolaus Kröger, Jacob Passweg, Amir Ali Hamidieh, Amal Al-Seraihy, Hildegard Greinix, José R. Nuñez, Ahmed Ibrahim, and Dietger Niederwieser more...
- Subjects
Transplantation ,Pediatrics ,medicine.medical_specialty ,High prevalence ,business.industry ,medicine.medical_treatment ,Incidence (epidemiology) ,Retrospective cohort study ,Hematology ,Disease ,Hematopoietic stem cell transplantation ,03 medical and health sciences ,surgical procedures, operative ,0302 clinical medicine ,immune system diseases ,030220 oncology & carcinogenesis ,medicine ,Transplantation Conditioning ,East mediterranean ,business ,030215 immunology - Abstract
Hematopoietic Stem Cell Transplantation (HSCT) activity was evaluated in the African (AFR)/EMRO region and compared to the global activity for the years 2006-2013. Data were obtained from 1570 teams in the 6 WHO continental regions. Of these, 29 (1.85%) of all teams were active in 12 of the 68 AFR/EMRO countries. They reported 2.331 (3.3%) of the worldwide 71.036 HSCT, and a transplant rate of 32.8 (TR; HSCT/10 million inhabitants; worldwide 128.5). This reflects still the lowest regional TR despite an increase of 90% since 2006. HSCT activity in AFR/EMRO countries was characterized by a higher use of allogeneic compared to autologous HSCT, an almost exclusive use of family donors, including haploidentical family donors. These findings contrast with the prevalence of autologous over allogeneic HSCT, and a higher frequency of unrelated HSCT in other parts of the world. Of note, the increase by 200% in HSCT for hemoglobinopathies from 2006 to 2013 (72 per year) in the AFR/EMRO region. This reflects the specific role of HSCT for these disease categories with high prevalence and incidence in the AFR/EMRO region. This report provides information for the competent authorities to foster adequate infrastructure. It urges transplant organization to optimize their cooperation. more...
- Published
- 2018
- Full Text
- View/download PDF
27. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia
- Author
-
Madan Jagasia, Yogesh Jethava, Andrea Bacigalupo, F Socola, Arnon Nagler, M. Mohty, Bipin N. Savani, and Simona Sica
- Subjects
Oncology ,medicine.medical_specialty ,Transplantation Conditioning ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Progenitor cell ,Transplantation ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematopoietic stem cell ,Hematology ,medicine.disease ,Leukemia, Myeloid, Acute ,surgical procedures, operative ,Graft-versus-host disease ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Radioimmunotherapy ,Immunology ,Stem cell ,business ,030215 immunology - Abstract
AML is currently the first indication for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as shown by international transplant registries. The conditioning regimens are classified as myeloablative conditioning, non-myeloablative or reduced intensity conditioning. Targeted radioimmunotherapy such as anti-CD45 antibody have also been added to the conditioning regimen in an attempt to improve tumor cell kill. Refinement of standard regimens has led to a reduction of non-relapse mortality, also in the older age group over 60 or 70 years of age. Relapse post allo-HSCT remains an important issue, especially for patients who undergo transplant with residual or refractory disease. In these patients, pre- and post-transplant interventions need to be considered. more...
- Published
- 2017
- Full Text
- View/download PDF
28. DEFIBROTIDE TREATMENT IN PAEDIATRIC PATIENTS WITH SEVERE/VERY SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAEMATOPOIETIC CELL TRANSPLANTATION: DEFIFRANCE INTERIM RESULTS
- Author
-
Anne Sirvent, M. Mohty, P. Schneider, M. Labopin, V. Gandemer, V. Bouvatier, and R. Martin
- Subjects
medicine.medical_specialty ,business.industry ,lcsh:RC633-647.5 ,Haematopoietic cell transplantation ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,Defibrotide ,Surgery ,Interim ,Immunology and Allergy ,Medicine ,Veno-Occlusive Disease ,business ,Paediatric patients ,medicine.drug - Published
- 2020
29. Respiratory Infection with Non-Tuberculous Mycobacteria After Allogeneic Hematopoietic Stem Cell Transplantation
- Author
-
Louis-Jean Couderc, E. Rivaud, A. Marcais, F. Suarez, Hélène Salvator, M. Mohty, E. Catherinot, Edouard Sage, L. Zemoura, A. Chabrol, L. Souchet, E. Cardot, C. Tcherakian, H. Vicaire, Eric Farfour, S. Nguyen, and E. Longchampt more...
- Subjects
business.industry ,medicine.medical_treatment ,Immunology ,Medicine ,Respiratory infection ,Hematopoietic stem cell transplantation ,business - Published
- 2019
- Full Text
- View/download PDF
30. P039/O03 Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib
- Author
-
L Ricard, V Jachiet, F Malard, Y Ye, N Stocker, S Rivière, P Senet, J-B Monfort, O Fain, M Mohty, B Gaugler, and A Mekinian
- Published
- 2019
- Full Text
- View/download PDF
31. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia : an ALWP/EBMT analysis
- Author
-
Jonathan Canaani, Dietrich W. Beelen, Arnon Nagler, M. Labopin, Nicolaus Kröger, Rose-Marie Hamladji, Gérard Socié, Miroslaw Markiewicz, Liisa Volin, Ghulam J. Mufti, A. Ghavamzadeh, G. Ehninger, Eric Beohou, Dietger Niederwieser, Renate Arnold, and M. Mohty more...
- Subjects
Adult ,Male ,Subset Analysis ,medicine.medical_specialty ,Multivariate analysis ,Adolescent ,Medizin ,Disease-Free Survival ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,Internal Medicine ,Humans ,Transplantation, Homologous ,Medicine ,Aged ,Retrospective Studies ,business.industry ,Incidence (epidemiology) ,Hazard ratio ,Middle Aged ,Total body irradiation ,Confidence interval ,3. Good health ,Transplantation ,Leukemia, Myeloid, Acute ,Treatment Outcome ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Cohort ,Female ,business ,Stem Cell Transplantation ,030215 immunology - Abstract
BACKGROUND Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years. OBJECTIVES To assess the incremental improvement of transplanted AML patients in the last two decades. METHODS Patients included in this analysis were adult AML patients who underwent allo-SCT from an HLA-matched sibling donor (MSD) or HLA-matched unrelated donor (MUD) in first remission. Patient outcomes were assessed between three cohorts according to the year of transplant (1993-2002, 2003-2007 and 2008-2012). RESULTS The analysis comprised a total of 20 187 patients of whom 4763 were transplanted between 1993 and 2002, 5835 in 2003 and 2007, and 9589 in 2008 and 2012. In multivariate analysis, leukaemia-free survival (LFS) rates were significantly improved in more recently transplanted patients compared to patients transplanted in 1993-2002 [Hazard ratio (HR) = 0.84, confidence interval (CI) 95%, 0.77-0.92; P = 0.003], a benefit which also extended to improved overall survival (OS; HR = 0.8, CI 95%, 0.73-0.89; P more...
- Published
- 2019
32. How to select donor, stem cell source, and conditioning regimen for haploidentical transplants with post-transplant cyclophosphamide for lymphoma: a report of the EBMT LWP
- Author
-
I. Yakoub-Agha, J. El Cheikh, Christelle Ferra, Stephen P. Robinson, J. L. Diez-Martin, Yener Koc, Corentin Orvain, Anna Sureda, Christoph Schmid, Mutlu Arat, Peter Dreger, L. Castagna, Johanna Tischer, M. Mohty, Didier Blaise, Vanderson Rocha, H. Labussière Wallet, Zafer Gulbas, Edouard Forcade, Herve Finel, Silvia Montoto, Alida Dominietto, Ali Bazarbachi, Ariane Boumendil, Yves Chalandon, L. Lopez Corral, and G. Gutiérrez García more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Post transplant cyclophosphamide ,business.industry ,Hematology ,General Medicine ,medicine.disease ,Lymphoma ,Conditioning regimen ,Internal medicine ,medicine ,Stem cell ,business - Published
- 2019
33. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
- Author
-
Mauricette Michallet, Takahiro Fukuda, Peter Bader, Ahmed Alaskar, Paul G. Richardson, C Peters, Mutlu Arat, Bipin N. Savani, Finn Bo Petersen, Erik Aerts, Tapani Ruutu, J.-H. Dalle, Fiona L Dignan, Fabio Ciceri, M. Abecassis, Mairead NiChonghaile, M. Mohty, Selim Corbacioglu, Arnon Nagler, E. Wallhult, S. Okamoto, Tamás Masszi, Didier Blaise, Florent Malard, R. F. Duarte, Anne Huynh, M Aljurf, Ali Bazarbachi, Enric Carreras, Ibrahim Yakoub-Agha, Frédéric Baron, A Pagliuca, Department of Medicine, Clinicum, Department of Oncology, Mohty, M, Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, Fabio, Corbacioglu, S., Dalle, J. H., Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A., Nichonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Savani, B. N., Wallhult, E., Yakoub Agha, I., Duarte, R. F., Carreras, E., and UAM. Departamento de Medicina more...
- Subjects
Pediatrics ,Veno-occlusive disease ,medicine.medical_treatment ,Hepatic Veno-Occlusive Disease ,Hematopoietic stem cell transplantation ,Disease ,Defibrotide ,Severity of Illness Index ,0302 clinical medicine ,Risk Factors ,Diagnosis ,VERSUS-HOST-DISEASE ,Medicine ,HIGH-RISK POPULATION ,MR-IMAGING FINDINGS ,Sinusoidal obstruction syndrome ,Mortality rate ,Hematopoietic Stem Cell Transplantation ,Hematology ,3. Good health ,030220 oncology & carcinogenesis ,medicine.drug ,Adult ,medicine.medical_specialty ,Hepatic veno-occlusive disease ,Patients ,Medicina ,3122 Cancers ,Sensitivity and Specificity ,03 medical and health sciences ,CONDITIONING REGIMEN ,VENOCCLUSIVE DISEASE ,Severity of illness ,Humans ,Special Report ,TISSUE-PLASMINOGEN ACTIVATOR ,Transplantation ,HEPATIC VENOOCCLUSIVE-DISEASE ,business.industry ,STEM-CELL TRANSPLANTATION ,medicine.disease ,Surgery ,Early Diagnosis ,MULTIORGAN FAILURE ,bacteria ,Complication ,business ,SIGNIFICANT TOXICITY ,Biomarkers ,030215 immunology - Abstract
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within a few weeks in most patients, the most severe forms result in multi-organ dysfunction and are associated with a high mortality rate ( > 80%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly as drugs have now proven to be effective and licensed for its treatment. Unfortunately, current criteria lack sensitivity and specificity, making early identification and severity assessment of SOS/VOD difficult. The aim of this work is to propose a new definition for diagnosis, and a severity-grading system for SOS/VOD in adult patients, on behalf of the European Society for Blood and Marrow Transplantation., FM was supported by educational grants from the 'Association for Training, Education and Research in Hematology, Immunology and Transplantation' (ATERHIT, Nantes, France) more...
- Published
- 2016
- Full Text
- View/download PDF
34. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT
- Author
-
Shigeo Fuji, Brian G. Engelhardt, Markus Kapp, K. Ohashi, André Tichelli, H. Einsele, Navneet S. Majhail, Bipin N. Savani, Michelle L. Griffith, Alicia Rovó, and M. Mohty
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,chemical and pharmacologic phenomena ,030209 endocrinology & metabolism ,Hematopoietic stem cell transplantation ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,Diabetes mellitus ,Diabetes Mellitus ,Humans ,Transplantation, Homologous ,Medicine ,Disease management (health) ,Intensive care medicine ,Transplantation ,business.industry ,Hematopoietic Stem Cell Transplantation ,Disease Management ,Hematology ,medicine.disease ,surgical procedures, operative ,Graft-versus-host disease ,Post transplant diabetes mellitus ,Hyperglycemia ,Allogeneic hsct ,Immunology ,business ,Solid organ transplantation ,therapeutics ,Forecasting ,030215 immunology - Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently develop glucose intolerance and post-transplant diabetes mellitus (PTDM). The clinical importance of PTDM and its detrimental impact on HSCT outcomes are under-recognized. After allo-HSCT, various mechanisms can contribute to the development of PTDM. Here we review information about hyperglycemia and PTDM after allo-HSCT as well as PTDM after solid organ transplantation and describe ways to manage hyperglycemia/PTDM after allogeneic HSCT. Taking into consideration a lack of well-established evidence in the field of allo-HSCT, more studies should be conducted in the future, which will require closer multidisciplinary collaboration between hematologists, endocrinologists and nutritionists. more...
- Published
- 2016
- Full Text
- View/download PDF
35. Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation
- Author
-
Dominique Bories, A.-C. Mamez, Ramdane Belhocine, François Delhommeau, O. Legrand, Ludovic Suner, Fanny Fava, Simona Lapusan, Pierre Hirsch, Ruoping Tang, Christophe Marzac, M. Mohty, and Luc Douay
- Subjects
Male ,0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Somatic cell ,Cord Blood Stem Cell Transplantation ,Biology ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Mutation ,Hematology ,Neoplasms, Second Primary ,Janus Kinase 2 ,Middle Aged ,Allografts ,medicine.disease ,Tissue Donors ,Leukemia, Myeloid, Acute ,Haematopoiesis ,Leukemia ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cord blood ,Immunology ,Stem cell - Abstract
Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation
- Published
- 2016
- Full Text
- View/download PDF
36. CD34
- Author
-
R, Mohty, E, Brissot, G, Battipaglia, A, Ruggeri, S, Sestili, C, Mediavilla, R, Belhocine, R, Dulery, M, Mohty, and F, Malard
- Subjects
Adult ,Male ,Reoperation ,Transplantation Conditioning ,Hematopoietic Stem Cell Transplantation ,Delayed Graft Function ,Graft vs Host Disease ,Antigens, CD34 ,Middle Aged ,Allografts ,Hematopoietic Stem Cells ,Cohort Studies ,Young Adult ,Humans ,Female ,Aged - Published
- 2018
37. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: Analysis of the FIRST trial
- Author
-
Dumontet, C. Hulin, C. Dimopoulos, M.A. Belch, A. Dispenzieri, A. Ludwig, H. Rodon, P. Van Droogenbroeck, J. Qiu, L. Cavo, M. Van De Velde, A. Lahuerta, J.J. Allangba, O. Lee, J.H. Boyle, E. Perrot, A. Moreau, P. Manier, S. Attal, M. Roussel, M. Mohty, M. Mary, J.Y. Civet, A. Costa, B. Tinel, A. Gaston-Mathé, Y. Facon, T. more...
- Abstract
Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors for TE grade ≥ 3 infection. The number of TE infections/month was highest during the first 4 months of treatment (defined as early infection). Of 1613 treated patients, 340 (21.1%) experienced TE grade ≥ 3 infections in the first 18 months and 56.2% of these patients experienced their first grade ≥ 3 infection in the first 4 months. Risk of early infection was similar regardless of treatment. Based on the analyses of data in 1378 patients through multivariate logistic regression, a predictive model of first TE grade ≥ 3 infection in the first 4 months retained Eastern Cooperative Oncology Group performance status and serum β 2 -microglobulin, lactate dehydrogenase, and hemoglobin levels to define high- and low-risk groups showing significantly different rates of infection (24.0% vs. 7.0%, respectively; P < 0.0001). The predictive model was validated with data from three clinical trials. This predictive model of early TE grade ≥ 3 infection may be applied in the clinical setting to guide infection monitoring and strategies for infection prevention. © 2018 The Author(s). more...
- Published
- 2018
38. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: A new classification from the European society for blood and marrow transplantation
- Author
-
Akif Yeşilipek, J.-H. Dalle, Fiona L Dignan, Isaac Yaniv, Enric Carreras, Francesco Locatelli, Rob Wynn, Selim Corbacioglu, M. Mohty, E. Trigoso, C Peters, A. Schulz, Peter Bader, Adriana Balduzzi, Simone Cesaro, Petr Sedlacek, Jacek Toporski, Paul G. Richardson, A.C. Lankester, B. Gruhn, A Pagliuca, K. Vetteranta, Elisabeth Wallhult, Brenda Gibson, Jacek Wachowiak, Marc Ansari, Jerry Stein, Tayfun Guengoer, K W Sykora, Corbacioglu, S, Carreras, E, Ansari, M, Balduzzi, A, Cesaro, S, Dalle, J, Dignan, F, Gibson, B, Guengoer, T, Gruhn, B, Lankester, A, Locatelli, F, Pagliuca, A, Peters, C, Richardson, P, Schulz, A, Sedlacek, P, Stein, J, Sykora, K, Toporski, J, Trigoso, E, Vetteranta, K, Wachowiak, J, Wallhult, E, Wynn, R, Yaniv, I, Yesilipek, A, Mohty, M, Bader, P, Clinicum, Lastentautien yksikkö, Children's Hospital, University of Helsinki, and HUS Children and Adolescents more...
- Subjects
Male ,Transplantation, venous occlusive disease, hematopoietic stem cell transplantation, childhood, complications, defibrotide ,Hepatic Veno-Occlusive Disease ,High dose chemotherapy ,HIGH-DOSE CHEMOTHERAPY ,0302 clinical medicine ,veno-occlusive disease, stem cell transplantation, prophylaxis, guidelines ,Risk Factors ,3123 Gynaecology and paediatrics ,hepatic venoocclusive disease ,HIGH-RISK NEUROBLASTOMA ,Medicine ,High risk neuroblastoma ,guidelines ,stem-cell transplantation ,DOPPLER-ULTRASONOGRAPHY ,ddc:618 ,Incidence ,VOD ,Hematology ,3. Good health ,Europe ,Treatment Outcome ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,030220 oncology & carcinogenesis ,Severity Criteria ,Female ,GEMTUZUMAB OZOGAMICIN EXPOSURE ,Veno-Occlusive Disease ,MYELOABLATIVE CHEMOTHERAPY ,Radiology ,prophylaxis ,Myeloablative chemotherapy ,medicine.medical_specialty ,stem cell transplantation ,INTRAVENOUS BUSULFAN ,03 medical and health sciences ,VENOCCLUSIVE DISEASE ,Humans ,veno-occlusive disease ,Special Report ,Transplantation ,Intravenous busulfan ,business.industry ,hematopoietic cell transplantation ,SOS/VOD ,children ,acute lymphoblastic-leukemia ,bacteria ,business ,030215 immunology - Abstract
The advances in hematopoietic cell transplantation (HCT) over the last decade have led to a transplant-related mortality below 15%. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of HCT that belongs to a group of diseases increasingly identified as transplant-related, systemic endothelial diseases. In most cases, SOS/VOD resolves within weeks; however, severe SOS/VOD results in multi-organ dysfunction/failure with a mortality rate > 80%. A timely diagnosis of SOS/VOD is of critical importance, given the availability of therapeutic options with favorable tolerability. Current diagnostic criteria are used for adults and children. However, over the last decade it has become clear that SOS/VOD is significantly different between the age groups in terms of incidence, genetic predisposition, clinical presentation, prevention, treatment and outcome. Improved understanding of SOS/VOD and the availability of effective treatment questions the use of the Baltimore and Seattle criteria for diagnosing SOS/VOD in children. The aim of this position paper is to propose new diagnostic and severity criteria for SOS/VOD in children on behalf of the European Society for Blood and Marrow Transplantation. more...
- Published
- 2018
39. S115 IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD
- Author
-
Frédéric Baron, Jordi Sierra, M. Labopin, M. Mohty, Pierre-Simon Rohrlich, E. Deconinck, J. M. Ribera Santasusana, T. de Revel, Eliane Gluckman, Arnon Nagler, Hélène Labussière-Wallet, Michael Potter, Stephen D. Robinson, Alessandro Rambaldi, and A. Ruggeri more...
- Subjects
medicine.medical_specialty ,Acute leukemia ,business.industry ,Internal medicine ,Medicine ,Hematology ,Disease ,business ,Cord blood transplantation - Published
- 2019
- Full Text
- View/download PDF
40. PF747 DEFIBROTIDE TREATMENT IN ADULTS WITH SEVERE OR VERY SEVERE VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC CELL TRANSPLANTATION: DEFIFRANCE STUDY INTERIM RESULTS
- Author
-
A. Petitprez, V. Bouvatier, Didier Blaise, M. Labopin, I. Yakoub-Agha, R. Peffault de Latour, and M. Mohty
- Subjects
Transplantation ,medicine.medical_specialty ,Hematopoietic cell ,business.industry ,Interim ,Internal medicine ,Medicine ,Veno-Occlusive Disease ,Hematology ,Defibrotide ,business ,Gastroenterology ,medicine.drug - Published
- 2019
- Full Text
- View/download PDF
41. PS1241 CHECKPOINT INHIBITOR TREATMENT BEFORE HAPLOIDENTICAL TRANSPLATATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES
- Author
-
Claude Lemarie, Valerio Maisano, Sabine Furst, F. Legrande, Boris Calmels, L. Castagna, M. Mohty, Raynier Devillier, Stefania Bramanti, Christian Chabannon, Carmelo Carlo-Stella, R. Bouabdallah, Jacopo Mariotti, A. Granada, Samia Harbi, C. Montes de Oca, Thomas Pagliardini, Pierre-Jean Weiller, Remy Dulery, Antonella Santoro, Didier Blaise, C. De Philippis, and Barbara Sarina more...
- Subjects
business.industry ,Immune checkpoint inhibitors ,Refractory Hodgkin Lymphoma ,Cancer research ,Medicine ,Hematology ,business - Published
- 2019
- Full Text
- View/download PDF
42. Venous thromboembolism in hematopoietic stem cell transplant recipients
- Author
-
A Neff, Shruti Chaturvedi, M. Mohty, U Savani, Bipin N. Savani, and Arnon Nagler
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,030204 cardiovascular system & hematology ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Maintenance therapy ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Humans ,cardiovascular diseases ,Intensive care medicine ,Lenalidomide ,Multiple myeloma ,Transplantation ,business.industry ,Hematopoietic Stem Cell Transplantation ,Venous Thromboembolism ,Hematology ,Allografts ,medicine.disease ,Thrombosis ,Thalidomide ,surgical procedures, operative ,Graft-versus-host disease ,030220 oncology & carcinogenesis ,Multiple Myeloma ,business ,medicine.drug - Abstract
Venous thromboembolism (VTE) is an increasingly recognized problem in the post-hematopoietic stem cell transplantation (HSCT) setting, with a lack of high-quality evidence-based data to recommend best practices. Few patients with hematologic malignancies and even fewer post-HSCT patients were included in randomized trials of VTE prophylaxis and treatment. Prior VTE, GVHD, infections and indwelling venous catheters are risk factors for thrombosis. The increasing use of post-transplant maintenance therapy with lenalidomide in patients with multiple myeloma adds to this risk after autologous HSCT. These patients are also at high risk of bleeding complications because of prolonged thrombocytopenia and managing the competing risks of bleeding and thrombosis can be challenging. This review aims to provide a practical, clinician-focused approach to the prevention and treatment of VTE in the post-HSCT setting. more...
- Published
- 2015
- Full Text
- View/download PDF
43. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
- Author
-
J. Y. Cahn, Jean-Valère Malfuson, Charlotte Jubert, Didier Blaise, T. Lamy, Yves Beguin, M. Ouzegdouh, Reman Oumedaly, Felipe Suarez, M. Mohty, J.-O. Bay, Nathalie Contentin, Luc Mathieu Fornecker, Vincent Levy, Patrice Chevallier, E. Deconink, Aliénor Xhaard, Anne-Claire Mamez, J. H. Bourhis, Marie-Cécile Michallet, Veronique Leblond, Sébastien Maury, Gaelle Guillerm, Stephane Vigouroux, Nathalie Fegueux, Son Nguyen, N. Maillard, Ibrahim Yakoub-Agha, Pascal Turlure, Fanny Rialland, Norbert Ifrah, Claude-Eric Bulabois, M. Boubaya, Anne Huynh, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), CHRU Brest - Service d'Hématologie (CHU-Brest-Hemato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hématologie, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre d'investigation clinique en cancérologie (CI2C), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU) more...
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Survival rate ,Retrospective Studies ,Transplantation ,Chemotherapy ,business.industry ,Hazard ratio ,Hematopoietic Stem Cell Transplantation ,Lymphoma, T-Cell, Peripheral ,Chemoradiotherapy ,Hematology ,Odds ratio ,Middle Aged ,Allografts ,medicine.disease ,3. Good health ,Surgery ,Lymphoma ,Survival Rate ,Graft-versus-host disease ,Lymphocyte Transfusion ,030220 oncology & carcinogenesis ,business ,Immunosuppressive Agents ,Follow-Up Studies ,030215 immunology - Abstract
International audience; Peripheral T-cell lymphoma carries a poor prognosis. To document a possible graft-versus-lymphoma effect in this setting, we evaluated the impact of immunomodulation in 63 patients with peripheral T-cell lymphoma who relapsed after allogeneic transplant in 27 SFGM-TC centers. Relapse occurred after a median of 2.8 months. Patients were then treated with non-immunologic strategies (chemotherapy, radiotherapy) and/or immune modulation (donor lymphocyte infusions (DLI) and/or discontinuation of immunosuppressive therapy). Median overall survival (OS) after relapse was 6.1 months (DLI group: 23.6 months, non-DLI group: 3.6 months). Among the 14 patients who received DLI, 9 responded and 2 had stable disease. Among the remaining 49 patients, a complete response accompanied by extensive chronic GvHD was achieved in two patients after tapering of immunosuppressive drugs. Thirty patients received radio-chemotherapy, with an overall response rate of 50%. In multivariate analysis, chronic GvHD (odds ratio: 11.25 (2.68–48.21), P=0.0009) and skin relapse (odds ratio: 4.15 (1.04–16.50), P=0.043) were associated with a better response to treatment at relapse. In a time-dependent analysis, the only factor predictive of OS was the time from transplantation to relapse (hazards ratio: 0.33 (0.17–0.640), P=0.0009). This large series provides encouraging evidence of a true GvL effect in this disease more...
- Published
- 2015
- Full Text
- View/download PDF
44. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)
- Author
-
Fabio Ciceri, Tapani Ruutu, Mairead NiChonghaile, Anne Huynh, Enric Carreras, Ibrahim Yakoub-Agha, P. G. Richardson, As. Alaskar, C Peters, M. Abecassis, B.N. Savani, M. Mohty, Selim Corbacioglu, Tamás Masszi, J.-H. Dalle, Mutlu Arat, Takahiro Fukuda, Peter Bader, Frédéric Baron, M Aljurf, Ali Bazarbachi, Florent Malard, Arnon Nagler, Fb. Petersen, Elisabeth Wallhult, Didier Blaise, R. F. Duarte, T. Pagluica, Erik Aerts, Mauricette Michallet, Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, Fabio, Corbacioglu, S, Dalle, Jh, Duarte, Rf, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, Nichonghaile, M, Pagluica, T, Peters, C, Petersen, Fb, Richardson, Pg, Ruutu, T, Savani, Bn, Wallhult, E, Yakoub Agha, I, and Carreras, E. more...
- Subjects
Position statement ,Adult ,medicine.medical_specialty ,medicine.medical_treatment ,genetic processes ,Hematopoietic stem cell transplantation ,Disease ,Defibrotide ,Postoperative Complications ,Risk Factors ,medicine ,Humans ,Vascular Diseases ,Prospective cohort study ,Intensive care medicine ,Special Report ,Transplantation ,Marrow transplantation ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,biochemical phenomena, metabolism, and nutrition ,enzymes and coenzymes (carbohydrates) ,surgical procedures, operative ,bacteria ,Veno-Occlusive Disease ,Complication ,business ,Biomarkers ,medicine.drug - Abstract
Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD) is a potentially life-threatening complication of hematopoietic SCT (HSCT). This review aims to highlight, on behalf of the European Society for Blood and Marrow Transplantation, the current knowledge on SOS/VOD pathophysiology, risk factors, diagnosis and treatments. Our perspectives on SOS/VOD are (i) to accurately identify its risk factors; (ii) to define new criteria for its diagnosis; (iii) to search for SOS/VOD biomarkers and (iv) to propose prospective studies evaluating SOS/ VOD prevention and treatment in adults and children. more...
- Published
- 2015
45. In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?
- Author
-
Stephane Vigouroux, R. Peffault de Latour, Jonathan Cornelissen, Eefke Petersen, Anne Huyn, Bruno Lioure, Johan Maertens, Charles Craddock, Harry C. Schouten, M. Mohty, Fabio Ciceri, Nigel H. Russell, Nathalie Fegueux, Arnon Nagler, Patrice Chevallier, M. Labopin, Lars Vindeløv, Gérard Socié, Lucía López Corral, J.Y. Cahn, Didier Blaise, Peffault De Latour, R., Labopin, M., Cornelissen, J., Vigouroux, S., Craddock, C., Blaise, D., Huyn, A., Vindelov, L., Maertens, J., Chevallier, P., Fegueux, N., Socie, G., Cahn, J. Y., Petersen, E., Schouten, H., Lioure, B., Russell, N., Corral, L. L., Ciceri, F., Nagler, A., Mohty, M., Hematology, MUMC+: MA Hematologie (9), Interne Geneeskunde, RS: GROW - Oncology, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy more...
- Subjects
Male ,medicine.medical_specialty ,Myeloid ,Transplantation Conditioning ,Tissue and Organ Procurement ,Filgrastim ,medicine.medical_treatment ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,Kaplan-Meier Estimate ,Disease-Free Survival ,Internal medicine ,medicine ,Living Donors ,Humans ,Sibling ,Aged ,Retrospective Studies ,Transplantation ,business.industry ,Siblings ,Graft Survival ,Age Factors ,Hematopoietic Stem Cell Transplantation ,Retrospective cohort study ,Hematology ,Middle Aged ,Allografts ,Histocompatibility ,Surgery ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,Treatment Outcome ,Female ,business ,Immunosuppressive Agents ,medicine.drug ,Follow-Up Studies - Abstract
Allogeneic hematopoietic transplantation is increasingly used in patients aged 55 years or more with AML. The question of whether outcomes can be improved with an allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older HLA-matched sibling (MSD, more than 55 years) is still unanswered. We thus analyzed outcomes in 714 patients aged 55 years and older with AML in first CR (CR1) who received PBSCs after a reduced-intensity conditioning hematopoietic cell transplant from a MUD (n=310) or a MSD (n=404) in a recent period (2005-2010). The 3-year cumulative incidences (CIs) of non-relapse mortality were 17% and 23% with MSD and MUD, respectively (P=0.17). The 3-year CIs of relapse were 37% and 30%, respectively (P=0.12), resulting in a 3-year CI of leukemia-free survival of 46% and 47%, respectively (P=0.51). The 3-year overall survival was 49% with both MSD and MUD. In conclusion, HLA-identical sibling donors aged 55 years or more should not be excluded because of age for patients aged 55 years and older with AML in CR1. more...
- Published
- 2015
- Full Text
- View/download PDF
46. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas
- Author
-
O. Tournilhac, R. Tabrizi, Noel Milpied, R. Bouabdallah, Patrice Chevalier, Adélaïde Doussau, S. Le Gouill, S. Furst, Julien Asselineau, S. Vigouroux, Didier Blaise, Kamal Bouabdallah, Patrice Ceballos, and M. Mohty more...
- Subjects
Adult ,Male ,medicine.medical_specialty ,Lymphoma, B-Cell ,Transplantation Conditioning ,Ibritumomab tiuxetan ,Graft vs Host Disease ,Aggressive lymphoma ,Gastroenterology ,Disease-Free Survival ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Transplantation, Homologous ,Cumulative incidence ,Prospective Studies ,Busulfan ,Antilymphocyte Serum ,Salvage Therapy ,business.industry ,Antibodies, Monoclonal ,Hematology ,Middle Aged ,Chemotherapy regimen ,Fludarabine ,Transplantation ,Regimen ,Treatment Outcome ,Oncology ,Immunology ,Female ,Neoplasm Recurrence, Local ,business ,Vidarabine ,Stem Cell Transplantation ,medicine.drug - Abstract
Background Patients with advanced B-cell non-Hodgkin's lymphoma (NHL) refractory to initial chemotherapy or relapsing after autologous stem-cell transplantation have a poor prognosis. Allogeneic stem-cell transplantation after reduced-intensity conditioning (RIC) regimen can be a therapeutic option. However, the high incidence of relapse remains a challenging issue. We speculated that the incorporation of 90Y-Ibritumomab tiuxetan into a fludarabine-based RIC regimen would improve the lymphoma control without overwhelming toxicity. Our aim was to evaluate the safety of 90Y-Ibritumomab tiuxetan in association with such a regimen in a prospective multicenter phase II trial. Patients and methods Thirty-one patients with advanced lymphoma from five distinct institutions were included between February 2008 and October 2010. Thirty patients in complete or partial response after failure of a median of 3 (range, 2–4) previous chemotherapy regimens including autologous transplant in 29 were evaluable for nonrelapse mortality (NRM) at day 100 post-transplant that was the primary end point. Results With a median follow-up of 32 months (range, 29–60 months), the 2-year event-free and overall survivals of the whole study group were both 80% [95 confidence interval (CI) 60.8% to 90.5%). The 100-day and 2-year post-transplant cumulative incidences of NRM were 3.3% (95% CI 0.2% to 14.9%) and 13.3% (95% CI 5.4% to 33.2%), respectively. The 2-year cumulative incidence of relapse was 6.7% (95% CI 1.7% to 25.4%). The cumulative incidences of grade II–IV and extensive chronic graft-versus-host disease were 27% and 14%, respectively. Conclusions For chemosensitive advanced high-risk B-cell lymphoma, the addition of 90Y-Ibritumomab tiuxetan to a RIC regimen based on fludarabine, busulfan and antithymocyte globulin followed by allogeneic transplant is safe and highly effective. clinicaltrials.gov : NCT00607854. more...
- Published
- 2015
- Full Text
- View/download PDF
47. Medullar toxicity after prolonged nitrous oxide exposure: an unexpected cause of bone marrow failure post allogeneic transplant
- Author
-
Marie-Thérèse Rubio, M. Mohty, Anne-Claire Mamez, Cohen M, Rostaing-Rigattieri S, Vozy A, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU) more...
- Subjects
inorganic chemicals ,Time Factors ,Adolescent ,Anemia ,Nitrous Oxide ,Bone Marrow Cells ,03 medical and health sciences ,0302 clinical medicine ,Bone Marrow ,Recurrence ,030202 anesthesiology ,medicine ,Humans ,Transplantation, Homologous ,Progenitor cell ,ComputingMilieux_MISCELLANEOUS ,Bone Marrow Transplantation ,Transplantation ,business.industry ,organic chemicals ,Bone marrow failure ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,equipment and supplies ,medicine.disease ,3. Good health ,Vitamin B 12 ,Treatment Outcome ,medicine.anatomical_structure ,Graft-versus-host disease ,Anesthesia ,Toxicity ,bacteria ,Female ,Bone marrow ,Stem cell ,business ,030217 neurology & neurosurgery - Abstract
Medullar toxicity after prolonged nitrous oxide exposure: an unexpected cause of bone marrow failure post allogeneic transplant
- Published
- 2016
- Full Text
- View/download PDF
48. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
- Author
-
H Ludwig, M Delforge, T Facon, H Einsele, F Gay, P Moreau, H Avet-Loiseau, M Boccadoro, R Hajek, M Mohty, M Cavo, M A Dimopoulos, J F San-Miguel, E Terpos, S Zweegman, L Garderet, M-V Mateos, G Cook, X Leleu, H Goldschmidt, G Jackson, M Kaiser, K Weisel, N W C J van de Donk, A Waage, M Beksac, U H Mellqvist, M Engelhardt, J Caers, C Driessen, and P Sonneveld more...
- Subjects
Cancer Research ,Oncology ,Hematology - Abstract
During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drugs classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.Leukemia accepted article preview online, 18 December 2017. doi:10.1038/leu.2017.353. more...
- Published
- 2017
49. Reduced-intensity vs reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted nonHodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
- Author
-
E. Deconinck, S. Vigouroux, A. Le Bourgeois, J.-O. Bay, Aude Charbonnier, R. Peffault de Latour, Nathalie Contentin, Ibrahim Yakoub-Agha, Patrice Chevallier, M. Labopin, Patrice Ceballos, Jérôme Cornillon, Tony Marchand, S. Chantepie, Mélanie Mercier, Stéphanie Nguyen, Claude-Eric Bulabois, M. Mohty, Ambroise Marçais, Didier Blaise, N. Maillard, Pascal Turlure, Etienne Daguindau, P.S. Rorhlich, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service greffe de moelle osseuse, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut de Cancérologie de la Loire Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Développement, institutions et analyses de long terme (DIAL), Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Laboratoire de Physique Nucléaire et de Hautes Énergies (LPNHE), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Pierre et Marie Curie - Paris 6 (UPMC), Microenvironnement et cancer (MiCa), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'Hématologie Clinique [Nantes] (Unité d'Investigation Clinique), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), ALWP-EBMT & Département d'hématologie et de thérapie cellulaire [AP-HP Hôpital Saint-Antoine], AP-HP - Hôpital Saint-Antoine, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias - Clermont Auvergne (CHELTER), Université Clermont Auvergne (UCA), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), and Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz more...
- Subjects
Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,Graft vs Host Disease ,Gastroenterology ,conditioning regimen ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,allogeneic stem-cell transplantation ,Humans ,Cumulative incidence ,busulfan ,ComputingMilieux_MISCELLANEOUS ,Aged ,Retrospective Studies ,Univariate analysis ,business.industry ,Incidence (epidemiology) ,Lymphoma, Non-Hodgkin ,non-Hodgkin lymphoma ,Hematopoietic Stem Cell Transplantation ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,Middle Aged ,medicine.disease ,Survival Analysis ,3. Good health ,Fludarabine ,Lymphoma ,Transplantation ,Graft-versus-host disease ,Oncology ,030220 oncology & carcinogenesis ,Female ,business ,Busulfan ,Vidarabine ,030215 immunology ,medicine.drug - Abstract
Background Fludarabine/busulfan-based conditioning regimens are widely used to perform allogeneic stem-cell transplantation (allo-SCT) in high-risk non-Hodgkin lymphoma (NHL) patients. The impact of the dose intensity of busulfan on outcomes has not been reported yet. Patients and methods This was a retrospective with the aim to compare the outcomes of NHL patients who received before allo-SCT a fludarabine/busulfan conditioning regimen, either of reduced intensity (FB2, 2 days of busulfan at 4 mg/kg/day oral or 3.2 mg/kg/day i.v.) (n = 277) or at a myeloablative reduced-toxicity dose (FB3/FB4, 3 or 4 days of busulfan at 4 mg/kg/day oral or 3.2 mg/kg/day i.v.) (n = 101). Results In univariate analysis, the 2-year overall survival (FB2 66.5% versus 60.3%, P = 0.33), lymphoma-free survival (FB2 57.9% versus 49.8%, P = 0.26), and non-relapse mortality (FB2 19% versus 21.1%, P = 0.91) were similar between both groups. Cumulative incidence of grade III–IV acute graft versus host disease (GVHD) (FB2 11.2% versus 18%, P = 0.08), extensive chronic GVHD (FB2: 17.3% versus 10.7%, P = 0.18) and 2-year GVHD free-relapse free survival (FB2: 44.4% versus 42.8%, P = 0.38) were also comparable. In multivariate analysis there was a trend for a worse outcome using FB3/FB4 regimens (overall survival: HR 1.47, 95% CI: 0.96–2.24, P = 0.08; lymphoma-free survival: HR: 1.43, 95% CI: 0.99–2.06, P = 0.05; relapse incidence: HR 1.54; 95% CI: 0.96–2.48, P = 0.07). These results were confirmed using a propensity score-matching strategy. Conclusion We conclude that reduced toxicity myeloablative conditioning with fludarabine/busulfan does not improve the outcomes compared with reduced-intensity conditioning in adults receiving allo-SCT for NHL. more...
- Published
- 2017
- Full Text
- View/download PDF
50. Cadaver-based Necrotizing Fasciitis Model for Medical Training
- Author
-
Matthew G Cravens, Bahareh Amini-Shervin, Richard Amini, Kurt M Mohty, William J. Adamas-Rappaport, Steven C Irving, Srikar Adhikari, and Nicholas Stea
- Subjects
education ,medicine.medical_specialty ,ultrasound ,necrotizing fasciitis ,business.industry ,Ultrasound ,High mortality ,General Engineering ,030208 emergency & critical care medicine ,medicine.disease ,Cadaver model ,Surgery ,03 medical and health sciences ,Orthopedics ,0302 clinical medicine ,Systemic toxicity ,Cadaver ,General Surgery ,Emergency Medicine ,Medical training ,Fresh frozen ,Medicine ,030212 general & internal medicine ,business ,Fasciitis - Abstract
Necrotizing fasciitis is a devastating infectious disease process that is characterized by extensive soft tissue necrosis along deep fascial planes, systemic toxicity, and high mortality. Ultrasound imaging is a rapid and non-invasive tool that can be used to help make the diagnosis of necrotizing fasciitis by identifying several distinctive sonographic findings. The purpose of this study is to describe the construction of a realistic diagnostic training model for necrotizing fasciitis using fresh frozen cadavers and common, affordable materials. Presently, fresh non-embalmed cadavers have been used at medical institutions for various educational sessions including cadaver-based ultrasound training sessions. Details for the preparation and construction of a necrotizing fasciitis cadaver model are presented here. This paper shows that the images obtained from the cadaver model closely imitate the ultrasound appearance of fluid and gas seen in actual clinical cases of necrotizing fasciitis. Therefore, it can be concluded that this cadaver-based model produces high-quality sonographic images that simulate those found in true cases of necrotizing fasciitis and is ideal for demonstrating the sonographic findings of necrotizing fasciitis. more...
- Published
- 2017
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.